Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 5 hours ago
- 1 min read
09/03/2026
Pfizer announced Phase 2 results of tilrekimig in AD (Ref)
Pfizer announced positive topline results from its Phase 2 study that evaluated tilrekimig (PF-07275315; trispecific antibody targets Il-4, IL-13 and TSLP) for the treatment of adult patients with moderate to severe atopic dermatitis (AD)
The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 compared to placebo
Tilrekimig was well-tolerated with a favorable safety profile
Based on encouraging results, the company planned to accelerate tilrekimig to Phase 3 development, with a pivotal study in AD on track to start this year
